Empasug-LG 25mg

Manufactured By Intra Life

product type tab

Composition Empagliflozin 25 mg + Linagliptin 5 mg IR

Package SIZE

( 10X10 )

100% Authentic
Products

Free
Shipping

Products
Return Policy

Information about Empasug-LG 25mg

Description:

  • Empasug-LG 25mg is a fixed-dose oral antihyperglycemic agent combining empagliflozin (25 mg) and linagliptin (5 mg). This dual-mechanism tablet is indicated for adults with type 2 diabetes mellitus (T2DM) to improve glycemic control. The combination leverages SGLT2 inhibition to promote urinary glucose excretion and DPP-4 inhibition to enhance insulin secretion and suppress glucagon. It is not indicated for type 1 diabetes or diabetic ketoacidosis.
  • As one of the trusted choices among empagliflozin tablet manufacturers, this formulation ensures consistent quality and clinical effectiveness.

Key Features:

  • Combines empagliflozin and linagliptin for complementary glycemic control

  • Supports HbA1c reduction and improved postprandial glucose regulation

  • Demonstrates cardiovascular and renal protection in clinical settings

  • Provides a once-daily oral dosing schedule to improve patient compliance

  • Well-suited for patients requiring dual antihyperglycemic therapy

  • Widely recommended by diabetes medicine wholesalers due to its effective dual-action mechanism

Usage Guidelines:

  • Take once daily, with or without food

  • Initiate therapy in adults not adequately controlled on monotherapy

  • Monitor renal function and glycemic response during use

Safety Profile:

  • Side effects may include nasopharyngitis, urinary tract infections, or headaches

  • Avoid in patients with eGFR <30 mL/min/1.73m², type 1 diabetes, or ketoacidosis

  • Monitor for ketoacidosis, hypovolemia, and signs of pancreatitis

Uses / Indications: Used in adults with type 2 diabetes mellitus (T2DM) to improve blood sugar control as an adjunct to diet and exercise. This combination of SGLT2 inhibitor (Empagliflozin) and DPP-4 inhibitor (Linagliptin) provides dual glucose-lowering effects. Not for type 1 diabetes or diabetic ketoacidosis.